Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2008

Open Access 01-12-2008 | Research

The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children

Authors: Stephen B Lambert, Kelly M Allen, Robert C Carter, Terence M Nolan

Published in: Respiratory Research | Issue 1/2008

Login to get access

Abstract

Background

Acute respiratory illnesses (ARIs) during childhood are often caused by respiratory viruses, result in significant morbidity, and have associated costs for families and society. Despite their ubiquity, there is a lack of interdisciplinary epidemiologic and economic research that has collected primary impact data, particularly associated with indirect costs, from families during ARIs in children.

Methods

We conducted a 12-month cohort study in 234 preschool children with impact diary recording and PCR testing of nose-throat swabs for viruses during an ARI. We used applied values to estimate a virus-specific mean cost of ARIs.

Results

Impact diaries were available for 72% (523/725) of community-managed illnesses between January 2003 and January 2004. The mean cost of ARIs was AU$309 (95% confidence interval $263 to $354). Influenza illnesses had a mean cost of $904, compared with RSV, $304, the next most expensive single-virus illness, although confidence intervals overlapped. Mean carer time away from usual activity per day was two hours for influenza ARIs and between 30 and 45 minutes for all other ARI categories.

Conclusion

From a societal perspective, community-managed ARIs are a significant cost burden on families and society. The point estimate of the mean cost of community-managed influenza illnesses in healthy preschool aged children is three times greater than those illnesses caused by RSV and other respiratory viruses. Indirect costs, particularly carer time away from usual activity, are the key cost drivers for ARIs in children. The use of parent-collected specimens may enhance ARI surveillance and reduce any potential Hawthorne effect caused by compliance with study procedures. These findings reinforce the need for further integrated epidemiologic and economic research of ARIs in children to allow for comprehensive cost-effectiveness assessments of preventive and therapeutic options.
Literature
1.
Fendrick AM, Monto AS, Nightengale B, Sarnes M: The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003, 163:487–494.CrossRefPubMed
2.
Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P: Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003, 22:S207–210.CrossRefPubMed
3.
Principi N, Esposito S, Gasparini R, Marchisio P, Crovari P: Burden of influenza in healthy children and their households. Arch Dis Child 2004, 89:1002–1007.CrossRefPubMedPubMedCentral
4.
Esposito S, Gasparini R, Bosis S, Marchisio P, Tagliabue C, Tosi S, Bianchi C, Crovari P, Principi N: Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005, 11:933–936.CrossRefPubMed
5.
Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, Bianchi C, Colombo GL, Principi N: Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 2006, 24:629–635.CrossRefPubMed
6.
Cohen GM, Nettleman MD: Economic impact of influenza vaccination in preschool children. Pediatrics 2000, 106:973–976.CrossRefPubMed
7.
Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G: Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005, 23:1284–1293.CrossRefPubMed
8.
Skowronski DM, Woolcott JC, Tweed SA, Brunham RC, Marra F: Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine 2006, 24:4222–4232.CrossRefPubMed
9.
Marchetti M, Kuhnel UM, Colombo GL, Esposito S, Principi N: Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 2007, 3:14–22.CrossRefPubMed
10.
11.
Coleman MS, Washington ML, Orenstein WA, Gazmararian JA, Prill MM: Interdisciplinary epidemiologic and economic research needed to support a universal childhood influenza vaccination policy. Epidemiol Rev 2006, 28:41–46.CrossRefPubMed
12.
13.
14.
Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50–55.CrossRefPubMed
15.
World Health Organization Writing Group: Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2006, 12:81–87.CrossRefPubMedCentral
16.
World Health Organization Writing Group: Nonpharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis 2006, 12:88–94.CrossRefPubMedCentral
17.
Lo JY, Tsang TH, Leung YH, Yeung EY, Wu T, Lim WW: Respiratory infections during SARS outbreak, Hong Kong, 2003. Emerg Infect Dis 2005, 11:1738–1741.CrossRefPubMedPubMedCentral
18.
Markel H, Lipman HB, Navarro JA, Sloan A, Michalsen JR, Stern AM, Cetron MS: Nonpharmaceutical interventions implemented by US cities during the 1918–1919 influenza pandemic. JAMA 2007, 298:644–654.CrossRefPubMed
19.
Lambert S, Allen K, Druce J, Birch C, Mackay I, Carlin J, Carapetis J, Sloots T, Nissen M, Nolan T: Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy pre-school aged children using parent-collected specimens. Pediatrics 2007, 120:e929-e937.CrossRefPubMed
20.
O'Grady K, O'Sullivan J, Gabriel S, Lambert S, Kefford M, Nolan T: Child and adolescent vaccine studies in Melbourne. Victorian Infectious Diseases Bulletin 2004, 7:33–36.
21.
22.
Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338:1405–1412.CrossRefPubMed
23.
Lambert S, O'Grady K-A, Gabriel S, Carter R, Nolan T: The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell 2004, 28:510–516.
24.
Lambert SB, O'Grady KF, Gabriel SH, Nolan TM: Respiratory illness during winter: a cohort study of urban children from temperate Australia. J Paediatr Child Health 2005, 41:125–129.CrossRefPubMed
25.
26.
27.
Briggs A, Gray A: The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998, 3:233–245.PubMed
28.
Jordan WS Jr, Badger GF, Dingle JH: A study of illness in a group of Cleveland families. XVI. The epidemiology of influenza, 1948–1953. Am J Hyg 1958, 68:169–189.PubMed
29.
Monto AS, Davenport FM, Napier JA, Francis T Jr: Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970, 122:16–25.CrossRefPubMed
30.
Taber LH, Paredes A, Glezen WP, Couch RB: Infection with influenza A/Victoria virus in Houston families, 1976. J Hyg (Lond) 1981, 86:303–313.CrossRef
31.
Fox JP, Hall CE, Cooney MK, Foy HM: Influenzavirus infections in Seattle families, 1975–1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982, 116:212–227.PubMed
32.
Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H, Fukuda K: Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342:232–239.CrossRefPubMed
33.
Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR: The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225–231.CrossRefPubMed
34.
Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, Waecker N, Cox NJ: Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000, 284:1677–1682.CrossRefPubMed
35.
Esposito S, Marchisio P, Cavagna R, Gironi S, Bosis S, Lambertini L, Droghetti R, Principi N: Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 2003, 21:3162–3168.CrossRefPubMed
36.
Ghendon YZ, Kaira AN, Elshina GA: The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 2006, 134:71–78.CrossRefPubMed
37.
Nokso-Koivisto J, Kinnari TJ, Lindahl P, Hovi T, Pitkaranta A: Human picornavirus and coronavirus RNA in nasopharynx of children without concurrent respiratory symptoms. J Med Virol 2002, 66:417–420.CrossRefPubMed
38.
van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, van Drunen K, Osterhaus A, Neijens H, Fokkens W: Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Allergy Immunol 2003, 14:363–370.CrossRefPubMed
39.
Hall JL, Katz BZ: Cost of influenza hospitalization at a tertiary care children's hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months. J Pediatr 2005, 147:807–811.CrossRefPubMed
40.
Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, Byington C, Pavia AT, Srivastava R: Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006, 118:2409–2417.CrossRefPubMed
41.
Keren R, Zaoutis TE, Saddlemire S, Luan XQ, Coffin SE: Direct medical cost of influenza-related hospitalizations in children. Pediatrics 2006, 118:e1321–1327.CrossRefPubMed
42.
Meltzer MI, Cox NJ, Fukuda K: The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5:659–671.CrossRefPubMedPubMedCentral
43.
Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB: Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001, 108:e24.CrossRefPubMed
44.
Meltzer MI, Neuzil KM, Griffin MR, Fukuda K: An economic analysis of annual influenza vaccination of children. Vaccine 2005, 23:1004–1014.CrossRefPubMed
45.
Nichol KL, Mendelman P: Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res 2004, 103:3–8.CrossRefPubMed
46.
Keren R, Wheeler A, Coffin SE, Zaoutis T, Hodinka R, Heydon K: ICD-9 codes for identifying influenza hospitalizations in children. Emerg Infect Dis 2006, 12:1603–1604.CrossRefPubMedPubMedCentral
47.
Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD: Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J 2006, 25:680–686.CrossRefPubMed
48.
Legg JP, Warner JA, Johnston SL, Warner JO: Frequency of detection of picornaviruses and seven other respiratory pathogens in infants. Pediatr Infect Dis J 2005, 24:611–616.CrossRefPubMed
49.
Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, Kainulainen L, Puhakka T, Jartti T, Toikka P, Lehtinen P, Routi T, Juven T: Burden of influenza in children in the community. J Infect Dis 2004, 190:1369–1373.CrossRefPubMed
50.
Bosis S, Esposito S, Niesters HG, Crovari P, Osterhaus AD, Principi N: Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses. J Med Virol 2005, 75:101–104.CrossRefPubMed
51.
Ehlken B, Ihorst G, Lippert B, Rohwedder A, Petersen G, Schumacher M, Forster J: Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr 2005, 164:607–615.CrossRefPubMed
52.
Turner J, Tran T, Birch C, Kelly H: Higher than normal seasonal influenza activity in Victoria, 2003. Commun Dis Intell 2004, 28:175–180.
53.
Sculpher MJ: The role and estimation of productivity costs in economic evaluation. Economic evaluation in health care: merging theory with practice 2 Edition (Edited by: Drummond MF, McGuire AE). Oxford: Oxford University Press 2001.
54.
Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T: Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006, 24:4934–4941.CrossRefPubMed
55.
Johannesson M: Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997, 11:385–388.CrossRefPubMed
56.
Zambon M, Hays J, Webster A, Newman R, Keene O: Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med 2001, 161:2116–2122.CrossRefPubMed
57.
Nichol KL: The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003, 21:1769–1775.CrossRefPubMed
58.
Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, Fewlass C, Watts M, Hessel C, Cordova J, Glezen WP: Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005, 23:1540–1548.CrossRefPubMed
59.
Centers for Disease Control and Prevention: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005, 54:893–897.
60.
61.
62.
63.
64.
65.
66.
Metadata
Title
The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children
Authors
Stephen B Lambert
Kelly M Allen
Robert C Carter
Terence M Nolan
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2008
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-9-11

Other articles of this Issue 1/2008

Respiratory Research 1/2008 Go to the issue

Research

Smad gene expression in pulmonary fibroblasts: indications for defective ECM repair in COPD

Research

RNA interference for CFTR attenuates lung fluid absorption at birth in rats

Research

Superoxide dismutase A antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses

Research

Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary disease

Research

Cryptococcus neoformans induces IL-8 secretion and CXCL1 expression by human bronchial epithelial cells

Research

Different effects of deep inspirations on central and peripheral airways in healthy and allergen-challenged mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits